B-HCG, Qualitative
The B-HCG, Qualitative test is a binary serum immunoassay reporting whether human chorionic gonadotropin is detected above the assay threshold. It confirms or excludes pregnancy with greater sensitivity than urine point-of-care tests, supports pre-procedural screening, and detects hCG in trophoblastic or germ-cell tumours;
1
Biomarkers
Blood (serum)
Sample
1–2 business days
Turnaround
No
Fasting
What is the β-hCG (Qualitative) test?
The B-HCG, Qualitative test is a binary serum immunoassay that reports whether human chorionic gonadotropin is present above the assay detection threshold. Practitioners order it when pregnancy must be confirmed or excluded with greater certainty than a point-of-care urine test can provide — for example, before administering teratogenic medication or anaesthesia, when symptoms suggest ectopic pregnancy but urine testing is negative, or when the patient reports irregular cycles and uncertain dates. Unlike quantitative β-hCG, which tracks doubling times and correlates with gestational age, the qualitative assay answers a single question: is hCG present? That simplicity makes it the test of choice for binary decision-making — proceed with a procedure, initiate or withhold a drug, or confirm that a pregnancy has completely resolved after miscarriage or termination. When the result is positive but clinical context is unclear, a quantitative β-hCG measurement and transvaginal ultrasonography follow to localise the pregnancy and assess viability.
What does the β-hCG (Qualitative) test measure?
Human chorionic gonadotropin is a glycoprotein hormone secreted by syncytiotrophoblast cells of the placenta following implantation. The intact molecule comprises an alpha subunit shared with luteinising hormone, follicle-stimulating hormone, and thyroid-stimulating hormone, and a unique beta subunit that confers immunological specificity. Serum β-hCG becomes detectable approximately 6–8 days after conception, doubling every 48–72 hours in early viable pregnancy, and peaks at 8–11 weeks of gestation before declining to a plateau that persists throughout the second and third trimesters. Outside pregnancy, detectable β-hCG may be produced by trophoblastic tumours, germ-cell neoplasms, and certain non-trophoblastic malignancies.
Qualitative β-hCG is the definitive serum test for pregnancy confirmation when urine point-of-care tests are equivocal or when clinical suspicion is high despite a negative urine result. It is more sensitive than urine assays and eliminates operator variation. A detected result confirms the presence of circulating hCG but does not indicate viability, location, or gestational age — quantitative β-hCG and pelvic ultrasonography provide that additional information. Detection of β-hCG in non-pregnant patients or men prompts investigation for gestational trophoblastic disease or germ-cell tumours.
Why is the β-hCG (Qualitative) test ordered?
- Confirmation or exclusion of early pregnancy when a urine point-of-care test is equivocal, negative despite clinical suspicion, or unavailable
- Pre-procedural screening before surgery, imaging with ionising radiation, or administration of teratogenic drugs (methotrexate, isotretinoin, certain anticonvulsants)
- Evaluation of suspected ectopic pregnancy in a patient with pelvic pain or vaginal bleeding and a negative or faint urine hCG
- Confirmation that β-hCG has returned to undetectable after spontaneous or therapeutic pregnancy loss, molar pregnancy, or ectopic pregnancy treatment
- Investigation of secondary amenorrhoea when menstrual history is unreliable or when symptoms (nausea, breast tenderness) suggest pregnancy
- Work-up of suspected gestational trophoblastic disease or germ-cell tumour in a non-pregnant woman or in a man with an unexplained pelvic or testicular mass
- Medico-legal documentation of pregnancy status in forensic, occupational, or insurance contexts where a binary laboratory result is required
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
Phlebotomy at LabCorp patient service centre or Access Medical Laboratories draw site; no fasting or special preparation. Document date of last menstrual period, date of suspected conception, recent pregnancy loss, or relevant medications (fertility treatment, hCG injections). Red-top or gel-separator tube; separate serum promptly.
Specimen requirements
Minimum 0.5 mL serum. Separate from cells within two hours of collection; serum is stable refrigerated for up to one week or frozen for longer storage. Note the performing laboratory for serial comparability, as detection thresholds differ slightly between assays.
What can affect β-hCG (Qualitative) results?
hCG secretion begins at implantation; testing before 6–8 days post-conception may yield a false-negative result, so retesting 48–72 hours later is warranted if clinical suspicion persists.
Endogenous antibodies that cross-react with assay reagents can produce false-positive or (rarely) false-negative results; a discrepancy between qualitative and quantitative hCG or between serum and clinical findings should prompt a heterophile-blocking repeat or dilution study.
Circulating hCG can remain detectable for days to weeks after pregnancy ends; document the timeline and, if clearance is in question, order serial quantitative measurements rather than a single qualitative test.
Choriocarcinoma, hydatidiform mole, testicular or ovarian germ-cell tumours, and certain non-trophoblastic cancers secrete hCG; an unexplained positive result in a non-pregnant patient requires oncological investigation.
Peri-menopausal and post-menopausal women may have low-level pituitary hCG secretion that can cause a weakly positive qualitative result; correlation with age, menstrual status, quantitative hCG, and FSH/LH helps distinguish physiological from pathological elevation.
Qualitative assays typically detect hCG above 5–25 mIU/mL; results near the threshold may be reported as equivocal or may toggle between detected and not detected across different platforms, so the performing laboratory should be noted for serial comparability.
What do β-hCG (Qualitative) results mean?
Elevated
Detected — pregnancy (intrauterine or ectopic), recent pregnancy loss with persistent hCG, gestational trophoblastic disease (molar pregnancy, choriocarcinoma), germ-cell tumour (testicular seminoma or non-seminoma, ovarian dysgerminoma), or rarely a non-trophoblastic malignancy that secretes hCG. In a woman of reproductive age with no history of recent pregnancy, detection warrants quantitative β-hCG and pelvic ultrasonography to localise a gestation or identify trophoblastic disease. In a man or post-menopausal woman, detection prompts imaging (testicular, pelvic, chest) and tumour-marker evaluation.
Normal
Not Detected is the normal state outside pregnancy and after complete clearance of hCG following pregnancy loss or treatment of trophoblastic disease. Detected is the normal and expected result throughout pregnancy from implantation until delivery.
Reduced
Not Detected — no circulating hCG above the assay threshold. This is the expected result in non-pregnant women and men and confirms absence of pregnancy or complete clearance after pregnancy loss. A not-detected result does not exclude very early pregnancy (before implantation or in the first few days after) or rare hCG-negative ectopic pregnancy, so clinical correlation and repeat testing are essential when suspicion is high.
Note: Qualitative β-hCG is a binary screen — detected or not detected — and does not quantify hormone concentration, assess viability, or localise the pregnancy. A positive result must be followed by quantitative β-hCG and ultrasonography when clinical questions remain. Heterophile interference, assay-specific thresholds, and timing relative to conception all influence interpretation, so correlation with clinical history and, when needed, repeat or confirmatory testing are non-negotiable.
Frequently asked questions
Qualitative β-hCG is binary — it reports detected or not detected, confirming the presence or absence of hCG. Quantitative β-hCG measures the exact concentration, tracks doubling times, and helps assess viability and gestational age. Qualitative is used for pregnancy confirmation; quantitative is used for monitoring.
How to access the β-hCG (Qualitative) test
The β-hCG (Qualitative) reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 193: Tubal ectopic pregnancy. (2018)
- Cervinski MA, et al. Qualitative versus quantitative hCG: the role of the laboratory in early pregnancy assessment. Clin Biochem. (2009)
- Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. (2010)
- Montagnana M, et al. Evaluation of the analytical performance of a new qualitative β-hCG assay for early pregnancy detection. Scand J Clin Lab Invest. (2011)
- Soper JT. Gestational trophoblastic disease: current evaluation and management. Obstet Gynecol. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.